Tip variant focal segmental glomerulosclerosis associated with interferon-β treatment of multiple sclerosis

Rhys Evans,1 Pandora Rudd,2 Paul Bass,1 Mark Harber1

1UCL Centre for Nephrology, London, UK
2Whittington Hospital, London, UK

Correspondence to
Dr Rhys Evans, rhysdrevans@gmail.com, rhys.evans3@nhs.net

DESCRIPTION

A 43-year-old Caucasian woman presented to the emergency department with a 1-week history of swelling of her hands and feet. She had multiple sclerosis (MS) and had been treated with interferon-β1a (6 million units weekly subcutaneously) for the past 15 months without significant side effects. Other medical problems included migraine, oesophagitis, obesity and depression. There was no history of lithium use.

On examination, she was systemically well but hypertensive (199/110) with pitting oedema to the knee. Urine dipstick was positive for blood (3+) and protein (4+). Her creatinine was 64 μmol/L, albumin 27 g/L, cholesterol 8.8 mmol/L and urinary protein:creatinine ratio (PCR) 1284 mg/mmol, consistent with the nephrotic syndrome. Erythrocyte sedimentation rate was 62 mm/h (C reactive protein 8 mg/L) with an otherwise unremarkable renal screen, including negative HIV, hepatitis B and C serology. Renal biopsy demonstrated epithelial cell injury with foam cell accumulation at the tip of the glomerulus near the beginning of the proximal tubule, consistent with tip variant focal segmental glomerulosclerosis (FSGS; figure 1).

Her interferon-β was stopped and she was treated with a ramipril 2.5 mg once daily, frusemide 40 mg once daily and tacrolimus 3 mg twice daily initially, adjusted to a target level of 4–7 ng/mL. Corticosteroids were not used due to their side effect profile and the patient’s specific comorbidities.

Her proteinuria improved (latest urinary PCR 100 mg/mmol), with resolution of her albumin and a reduction in cholesterol to 5.5 mmol/L, but her creatinine rose to 119 μmol/L (figure 2A,B). Whether this is secondary to calcineurin inhibitor effect, her disease process or another factor is unclear. She remains off specific treatment for her MS without symptomatic relapse.

The nephrotic syndrome is a rare complication of treatment with interferon-β. Collapsing FSGS (in addition to minimal change disease and membrano-proliferative glomerulonephritis) is a recognised pattern of glomerular injury.1–3 This is the first report of the nephrotic syndrome caused by tip variant FSGS in the setting of interferon-β treatment. This morphological variant of FSGS is usually idiopathic (with high shear stress and tuft prolapse responsible for the morphogenesis) and has a favourable response to treatment. In this case, proteinuria significantly improved with cessation of interferon-β and immunosuppression with tacrolimus.

Learning points

▸ The nephrotic syndrome is a rare complication of treatment with interferon-β.
▸ Tip variant and collapsing focal segmental glomerulosclerosis may be seen in the setting of interferon-β treatment.
▸ It is important to recognise the morphological pattern of glomerular injury as this may affect outcome with more favourable responses seen with the tip as opposed to the collapsing variant.

Figure 1 Renal biopsy (H&E stain) demonstrating tip variant focal segmental glomerulosclerosis (arrowed). Epithelial cell injury with foam cell accumulation is seen at the tip of the glomerulus near the beginning of the proximal tubule.
CONTRIBUTORS

RE, PR and MH were equally clinically involved with the clinical care of the patient and preparation of the manuscript. PB prepared and reported the histology and reviewed the manuscript prior to submission. RE made corrections to the manuscript post initial submission.

COMPETING INTERESTS

None.

PATIENT CONSENT

Obtained.

PROVENANCE AND PEER REVIEW

Not commissioned; externally peer reviewed.

REFERENCES


Figure 2  Reduction in proteinuria (A) and rise in creatinine (B) with time after cessation of interferon-β and treatment with ACE inhibitor, loop diuretic and tacrolimus.

![Figure 2](Image)